Novo Holdings A/S, the majority shareholder of Novo Nordisk A/S, is all set to venture out on its own in Asia as an increased focus on innovation and research, as well as the region’s growth and demographics, present compelling investment opportunities.
With an initial focus on China, Singapore and other Southeast Asian countries, the company, which had already tested the waters through an earlier Chinese partnership, will now study prospects across the